Outlook Therapeutics, Inc. (NASDAQ:OTLK) will release its third quarter earnings report before the opening bell on Friday, Aug. 14.
Analysts expect the Iselin, New Jersey-based company to report a quarterly loss of 8 cents per share, versus a loss of 44 cents per share in the year-ago period. The consensus estimate for OTLK’s quarterly revenue is $966.67 thousand. It reported $1.5 million last year, according to Benzinga Pro.
On Aug. 12, Outlook Therapeutics announced the pricing of $55.0 million public offering of common stock and warrants.
Shares of Outlook Therapeutics fell 19.2% to close at $0.89 on Thursday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
